Gilead Sciences, Inc. The stock took an early morning dive and has been in the red since. However, minutes ago, the stock started spiking toward the green as the result of a takeover rumor. Of course, our partners at Trade Ideas were the first to alert us to the movement. The rumors suggest that Sanofi SNY is interested in purchasing the company. However, the rumors are quite vague.
There is no insinuation of what the price of the takeover might be, nor when it will happen. In fact, we see them all the time. The truth is that very few of these rumors ever come to fruition. Stop wasting your time!
Find winning trades in minutes with Trade Ideas! While the rumor is vague, the takeover proposition does make sense. So, this one could go either way. Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!
Save my name, email, and website in this browser for the next time I comment. Notify me of follow-up comments by email. Notify me of new posts by email. CNA Finance. Archived Articles.
Subscribe Today! First Name. Please enter your comment! Please enter your name here. You have entered an incorrect email address! Joshua Rodriguez - July 15, 0. When I first Joshua Rodriguez - February 20, 0. There are tons of trading tools out there, but none of them are quite like TradeMiner. February 20, The biotech heavyweight told the investing community a week ago today that its top line will likely dip yet again this year thanks to falling hep C drug sales and the slower-than-expected commercialization of its anti-cancer cell therapy Yescarta.
Wall Street, for its part, is even less optimistic about the big biotech's near-term prospects. The average analyst estimate has the biotech's annual sales declining for the next two full years. That's a surprising take to be sure, given the strong possibility that Gilead's blockbuster-in-waiting, filgotinib, will likely hit the market soon.
The big deal is that the biotech's market capitalization has been bumping up against its five-year low lately thanks to this rather anemic outlook. In response, Jefferies' analyst Michael Yee published a note last week suggesting that Gilead might now be an attractive takeover target.
Its large-cap biopharma peers Allergan and Celgeneafter all, both turned into top acquisition targets when their respective market caps bottomed out. Is a possible takeover reason enough to buy Gilead's stock right now? Let's take a deeper look to find out. The main reason shareholders should mull over this idea is that Gilead's management would obviously demand a healthy premium in a takeover scenario.
That's a decent payday for the biotech's long-suffering shareholders, to be sure. When it comes to acquisitions, size most definitely matters. Pfizer doesn't come across as a likely suitor, either -- for a multitude of reasons.
Bay Area-Based Gilead Sees Potential Legal Conflict With China Over Its Coronavirus Drug
Chief among them, the pharma giant recently announced plans to slim down to unlock the latent growth potential of newer products such as breast cancer medication Ibrance. Pfizer does reportedly have interest in pursuing additional bolt-on acquisitions to flesh out its emerging growth portfolio. But the company seems intent on sticking to small-to-mid-sized deals to achieve this key operational goal.
Pfizer and Gilead also don't share a whole lot of clear-cut synergies.
AstraZeneca And Gilead Sciences Merger Rumors - Something To Watch
As such, it's hard to imagine that Pfizer would have any serious interest in buying Gilead, either. Gilead is almost certainly not going to be the next Allergan or Celgene. The long and short of it is that the big biotech is still far too large to be consumed by one of its peers, despite its prolonged trough period. So, if you're hoping for a quick buck on a buyout scenario, you might want to look elsewhere.
Gilead simply doesn't fit the bill. Investing Best Accounts. Stock Market Basics. Stock Market. Industries to Invest In.
Getting Started. Planning for Retirement. Retired: What Now? Personal Finance. The Ascent. About Us. Who Is the Motley Fool? Fool Podcasts. New Ventures.As corporations and governments rush to develop an effective treatment for COVID, medicines have become the targets of partisan praise and ire, helping misinformation about them spread online. Why is Fauci pushing Remdesivir? It was invented by Fauci and Gates. While clinical trials on the drugs remain ongoing, neither hydroxychloroquine nor remdesivir has been proven effective against COVID Bill Gates and Dr.
Remdesivir is an antiviral medication developed by the pharmaceutical company Gilead Sciences. The company has researched the drug sinceoriginally as a potential treatment for hepatitis C and respiratory syncytial virus and then later for the Ebola virus and now COVID During Ebola epidemic, Gilead and the U.
Initial studies from joint research groups were promisingthough the drug was never ultimately deployed against Ebola. Gilead first received a patent for the drug as a treatment for Ebola in In fallGilead applied for two patents for remdesivir, one for combatting coronaviruses and another for filoviruseswhich were both approved in spring More: Gilead Sciences reports positive drug results for remdesivir as coronavirus treatment.
When the new coronavirus, SARS-CoV-2, began to spread, remdesivir was one of only a handful of drugs known to combat coronaviruses. Medical experts found the study significant as the first effective clinical drug trial for a COVID treatment. Gilead maintains a monopoly on remdesivir in the United States and is consequently the only company set to profit from its use as a COVID treatment.
Fauci, the director of the National Institute of Allergy and Infectious Diseases, is not cited anywhere as an inventor or patent owner of the drug and has not authored any research studying remdesivir. While Fauci has also said that early trials of remdesivir on coronavirus patients are a positive sign, he has also cautioned against prematurely celebrating.
As remdesivir is wholly owned by Gilead Sciences, Fauci is not legally entitled to any profits from remdesivir.
That said, Fauci did not directly conduct this research; neither he nor the NIH stand to profit from its results. The National Institutes of Health confirmed that Fauci has not authored any studies on remdesivir and does not own stock in any biomedical or pharmaceutical companies. Owning financial assets in pharmaceutical firms like Gilead would also be required to be publicly disclosed per the agency's ethics policy. The NIH now recommends remdesivir be used "in hospitalized patients with severe disease," meaning any case where a the patient needs the use of a ventilator.
Similarly, Gates was not involved in the development of remdesivir or research into the drug. Gates mentioned remdesivir in an April 23 essay about global responses to the coronavirus.
Gilead Sciences is the only organization legally allowed to profit from the sale of remdesivir. Anthony Fauci were not involved in the development of the drug and are not set to profit from its sale. The two have both spoken positively about remdesivir but have also both cautioned that the drug is only to be used in critically ill patients and should be used in concert with other treatments.
Thank you for supporting our journalism. You can subscribe to our print edition, ad-free app or electronic newspaper replica here. The claim: Bill Gates and Dr. Anthony Fauci created and are set to profit from the drug remdesivir As corporations and governments rush to develop an effective treatment for COVID, medicines have become the targets of partisan praise and ire, helping misinformation about them spread online.
The origins of remdesivir Remdesivir is an antiviral medication developed by the pharmaceutical company Gilead Sciences. More: Gilead Sciences reports positive drug results for remdesivir as coronavirus treatment When the new coronavirus, SARS-CoV-2, began to spread, remdesivir was one of only a handful of drugs known to combat coronaviruses.
The navigation could not be loaded.South Korea on Friday approved an early stage clinical trial of Celltrion Inc's experimental COVID treatment drug, making it the country's first such antibody drug to be tested on humans. Celltrion's antibody treatment is directed against the surface of the virus and designed to block it from locking on to human cells.
Here are five for investors to consider. The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates. Yahoo Finance. Sign in. Sign in to view your mail. Finance Home. Gilead Sciences, Inc. Currency in USD. Add to watchlist. Summary Company Outlook. Trade prices are not sourced from all markets. Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies.
Bullish pattern detected. Double Moving Average Crossover. View all chart patterns. Performance Outlook Short Term. Mid Term. Long Term. Previous Close Volume 15, Market Cap Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Research that delivers an independent perspective, consistent methodology and actionable insight. Press Releases. Advertise With Us. All rights reserved. Data Disclaimer Help Suggestions. Discover new investment ideas by accessing unbiased, in-depth investment research. Day's Range. Beta 5Y Monthly. Earnings Date. Ex-Dividend Date. Jun 11, We recommend taking advantage of this by investing in Gilead Sciences, which has strong appreciation potential, with or without an acquisition.
The combined company would be worth almost a quarter of a trillion. While the rumors continue to change, and some state the merger discussions aren't actually active, as we'll see throughout this article, this potential merger is one to watch.
Gilead Sciences and AstraZeneca - Bloomberg. Gilead Sciences has an incredibly impressive portfolio of assets that justify the company's valuation and then some in our opinion.
You can read our last detailed analysis of Gilead Sciences here. However, some of the company's other businesses are exciting. For example, the company's HIV business is the company's largest and the company is increasingly moving patients to TAF based regimens. At the same time, Gilead Sciences has a number of potential exciting growth assets. The company's Yescarta revenue is expected to grow. That means that not only will the company's existing drugs generate strong revenue, but the company's new drugs can expand its revenue.
This will support continued cash flow into the s. AstraZeneca is another company that merges well with Gilead Sciences. That's because not only does the business have significant cash flow potential but it has significant growth potential.
AstraZeneca is focused on strong product sales and strong cash flow.
3 Gilead-Heavy ETFs To Watch Amid The AstraZeneca-Gilead Rumor
However, despite that, the company is experiencing rapid growth from its core portfolio, specifically oncology. This is an area where Gilead Sciences is trying to grow, and the potential synergies are enormous. However, it's worth noting that AstraZeneca is coming into this with a significant position of revenue and cash flow.
So let's take a look at what an acquisition would look like. Gilead Sciences is a company that, like Celgene, has had a difficult time since the company's prized asset has had a difficult time. So we'll use the Bristol-Myers Squibb acquisition of Celgene as our reference point. We'll assume that the same is true for this acquisition. Gilead Sciences has debt at less than 1. After interest, the company could pay down the entire debt from the deal in 4 years, while having strong cash flow generation abilities.
That potential deal could mean strong rewards for shareholders. That's a great valuation at the current positioning. Our view on this acquisition is that, obviously, while the details are sparse there is significant potential. Additionally, the acquisition would enable the companies to take advantage of low interest rates.
Gilead Sciences can raise 7-year debt at less than 1.The Foster City-based pharmaceutical company Gilead Sciences, which specializes in antiviral drugs, recently donated some of its experimental drug remdesivir for use in studying potential treatments for the Wuhan coronavirus. But a legal fight is brewing after Gilead applied for a Chinese patent for the drug inand still has not received one, and a group of researchers in Wuhan just applied for their own patent for Gilead's drug last month.
As the coronavirus outbreak worsens in central China, doctors have yet to identify a drug treatment that is effective against the virus. Remdesivir, which was developed to treat Ebola, may be an effective treatment against the family of coronaviruses. It is currently being used in combination with an HIV drug, ritonavir, to treat a pair of Chinese nationals with the coronavirus at a hospital in Rome after they became ill in Italy, as the New York Times reports.
But now as more doctors want to try treating patients with the drug near ground zero of the outbreak in Wuhan, the government-run Wuhan Institute of Virology announced this week that it had applied for a "use patent" for remdesivir. Their patent specifies the use of the drug to treat the novel coronavirus, while Gilead's three-plus-year-old patent application only specified using remdesivir to treat the family of coronaviruses. The Chinese researchers' application was filed January As the Associated Press reportsthis all comes back to the trade war with China, and the country's practice of "abus[ing] its regulatory system to pressure foreign companies to hand over valuable technology.
Ryan McKeel, a spokesperson for Gilead, tells the AP, "Gilead has no influence over whether a patent office issues a patent to the Chinese researchers.
For their part, the Chinese authorities have acknowledged that there may be "intellectual property barriers," but they said the patent application had been made in order to "protect national interests. Per the AP, "China has the right under World Trade Organization rules to declare an emergency and compel a company to license a patent to protect the public. Clinical trials involving remdesivir and other antiviral treatments — as well as some traditional Chinese remedies — are set to begin soon.
Remdesivir has yet to be approved for treatment of anything, anywhere in the world. But Gilead said last week it would be cooperating with Chinese health authorities to study the use of the drug. As of Thursday there were over 28, cases of coronavirus infection reported in mainland China, with 24 more in Hong Kong, and elsewhere in Asia.
The death toll from the virus now stands atand that now includes the whistleblower doctor who was reprimanded by the Chinese government for spreading "rumors" about the new virus back in December. As the AP reports, year-old ophthalmologist Dr. Li Wenliang himself succumbed to the virus this week at Wuhan Central Hospital. On the hospital's social media account, it said, "We deeply regret and mourn this. Stay up to date! Share this.South Korea on Friday approved an early stage clinical trial of Celltrion Inc's experimental COVID treatment drug, making it the country's first such antibody drug to be tested on humans.
Celltrion's antibody treatment is directed against the surface of the virus and designed to block it from locking on to human cells.Gilead sets U.S. price for Covid-19 drug remdesivir at $3,120 for typical treatment
Here are five for investors to consider. The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates. Yahoo Finance. Sign in. Sign in to view your mail. Finance Home. Gilead Sciences, Inc. Currency in USD. Add to watchlist. Summary Company Outlook.
Trade prices are not sourced from all markets. Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies. Bullish pattern detected. Double Moving Average Crossover. View all chart patterns. Performance Outlook Short Term. Mid Term.
Long Term. Previous Close Volume 15, Market Cap Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Research that delivers an independent perspective, consistent methodology and actionable insight.
- 97 civic cranks but wont start
- il labirinto e leresia. la politica urbanistica a napoli tra emergenza e
- running total in rdlc report
- frcr physics lectures
- pubg lite win64 shipping exe application error
- groot oswego il
- what are 3 database examples
- keras datasets
- valpantena corvina 2010
- jazz bass knobs
- taupo death notices today
- fps drop csgo
- peanut exporting countries
- bolt and nut size chart